Warning letter
Boothwyn Pharmacy, LLC: warning letter of Jan 16, 2026
FDA warning letter 717525 · Center for Drug Evaluation and Research (CDER)
Key facts
| Reference number | 717525 |
|---|---|
| Company | Boothwyn Pharmacy, LLC |
| Subject | Compounding Pharmacy/Adulterated Drug Products |
| Issue date | Jan 16, 2026 |
| Posted date | Feb 10, 2026 |
| Issuing office | Center for Drug Evaluation and Research (CDER) |
| Product type | Drugs |
| Inspection city | Kennett Square |
| Inspection ZIP | 19348 |
| Inspection start date | May 12, 2025 |
| Letter on fda.gov | fda.gov |
At a glance
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: